Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis

Abstract

The systemic inflammatory response predicted poor survival in patients with renal cell carcinoma.

Prognostic Significance of C-reactive Protein in Urological Cancers: a Systematic Review and Meta-analysis

“…Numerous studies have shown that CRP is a significant prognostic factor for RCC patients treated with surgery and/or systemic therapy. Our also evidence demonstrates CRP is associated with poor prognosis of RCC which is consistent with a previous meta-analysis study (Wu et al, 2011). The prognostic significance of CRP has been shown with its power for in urological cancers.…”

Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers

“…Thus, the plasma concentration of C-reactive protein in RCC-bearing patients (Hu et al, 2014;Ito et al, 2006;Jagdev et al, 2010;Karakiewicz et al, 2007;Lamb, McMillan, Ramsey, & Aitchison, 2006;Steffens et al, 2012) and the presence of an inflammatory gene signature in RCC (Romero et al, 2006;Tan et al, 2011) are linked to a higher tumor grade and positive metastatic status at diagnosis and poor prognosis. In addition, other inflammatory markers are related to poor survival in RCCbearing patients, including an augmented erythrocyte sedimentation rate, leukocytosis, thrombocytosis, and the increased plasmatic concentrations of IL-6 and TNF-α (Dosquet, Coudert, Lepage, Cabane, & Richard, 1997;Dosquet et al, 1994;Escudier et al, 2014;Fox et al, 2013;Negrier et al, 2004;Pichler et al, 2013;Wu et al, 2011;Yoshida et al, 2002). In vitro studies reinforce this concept, since several proinflammatory cytokines (eg, IL-6, TNF-α, hypoxia-inducible factor-α, and matrix metalloproteinase-2) are preferentially produced by the RCC cell lines exhibiting the highest malignant potential (Chuang et al, 2008;Ho et al, 2012;K€ onig et al, 1999).…”

The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma

“…An elevated PLT level was associated with poor OS (HR 2.24, 95% CI 1.87–2.67, p < 0.001) and CSS (HR 2.59, 95% CI 1.92–3.48, p < 0.001) in the analysis of all stages together. In localized disease, elevated PLT count was associated with poor CSS (HR 5.09, 95% CI 2.41–10.73, p < 0.001) and RFS (HR 6.68, 95% CI 3.35–13.34, p < 0.001) [33, 34]. Additionally, an elevated PLT level was significantly associated with TNM stage (OR 3.11, 95% CI 1.59–6.06, p = 0.001), pathological T stage (OR 3.13, 95% CI 2.60–3.77, p < 0.001), lymph node metastasis (OR 4.01, 95% CI 2.99–5.37, p < 0.001), distant metastasis (OR 3.85, 95% CI 2.46–6.04, p < 0.001), Fuhrman grade (OR 3.70, 95% CI 3.00–4.56, p < 0.001), tumor size (OR 4.69, 95% CI 2.78–7.91, p < 0.001), and Eastern Cooperative Oncology Group score (OR 5.50, 95% CI 3.26–9.28, p < 0.001) [34].…”